Search
The Rio Tinto Children’s Diabetes Centre is committed to increasing the community voice in diabetes research at all levels to ensure our research is
People living with Type 1 diabetes (T1D) can participate in all forms of physical activity, but it can sometimes be a little more challenging.
Check out the Centre's video library here
Our goal is to accelerate the dissemination and implementation of evidence-based models of care for children and young people living with Type 1 Diabetes.
A new research study conducted by Professor Jeneva Ohan and Dr Keely Bebbington aims to develop our understanding of how adolescents navigate these disclosure decisions, and how we can support them to feel more confident when talking to others about their diabetes.
Type 1 diabetes is well-recognised as a continuum heralded by the development of islet autoantibodies, progression to islet autoimmunity causing beta cell destruction, culminating in insulin deficiency and clinical disease. Abnormalities of glucose homeostasis are known to exist well before the onset of typical symptoms.
Technology use, including continuous glucose monitoring (CGM) and insulin pump therapy, is associated with improved outcomes in youth with type 1 diabetes (T1D). In 2017 CGM was universally funded for youth with T1D in Australia. In contrast, pump access is primarily accessed through private health insurance, self-funding or philanthropy.
To assess relationships between continuous glucose monitoring (CGM) time in range (TIR), 70-180 mg/dL, time below range (TBR), <70 mg/dL, time above range (TAR), >180 mg/dL, and glucose coefficient of variation (CV) in relation to currently recommended clinical CGM targets for older people, which recommend reduced TIR and TBR targets relative to the general type 1 diabetes population.
Tim Jones MBBS DCH FRACP MD Co-head, Diabetes and Obesity Research Co-head, Diabetes and Obesity Research Areas of research expertise: Diabetes